| Defining the clinical course of multiple sclerosis FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 8488* | 2014 |
| Cognitive dysfunction in multiple sclerosis SM Rao Multiple sclerosis and related disorders: Clinical guide to diagnosis …, 2019 | 3031 | 2019 |
| B-cell depletion with rituximab in relapsing–remitting multiple sclerosis SL Hauser, E Waubant, DL Arnold, T Vollmer, J Antel, RJ Fox, A Bar-Or, ... New England Journal of Medicine 358 (7), 676-688, 2008 | 2859 | 2008 |
| Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis RJ Fox, DH Miller, JT Phillips, M Hutchinson, E Havrdova, M Kita, M Yang, ... New England Journal of Medicine 367 (12), 1087-1097, 2012 | 1631 | 2012 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 1075 | 2018 |
| Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients R Dutta, J McDonough, X Yin, J Peterson, A Chang, T Torres, T Gudz, ... Annals of neurology 59 (3), 478-489, 2006 | 1003 | 2006 |
| Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial A Bar‐Or, PAJ Calabresi, D Arnold, C Markowitz, S Shafer, LH Kasper, ... Annals of neurology 63 (3), 395-400, 2008 | 615 | 2008 |
| Treatment of neuromyelitis optica with rituximab A Jacob, BG Weinshenker, I Violich, N McLinskey, L Krupp, RJ Fox, ... Arch Neurol 65 (11), 1443-8, 2008 | 550 | 2008 |
| Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic … LS Brady, HJ Whitfield, RJ Fox, PW Gold, M Herkenham The Journal of clinical investigation 87 (3), 831-837, 1991 | 428 | 1991 |
| Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patients R Dutta, A Chang, MK Doud, GJ Kidd, MV Ribaudo, EA Young, RJ Fox, ... Annals of neurology 69 (3), 445-454, 2011 | 374 | 2011 |
| Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function D Ontaneda, AJ Thompson, RJ Fox, JA Cohen The Lancet 389 (10076), 1357-1366, 2017 | 372 | 2017 |
| MRI findings in Susac’s syndrome JO Susac, FR Murtagh, RA Egan, JR Berger, R Bakshi, N Lincoff, ... Neurology 61 (12), 1783-1787, 2003 | 365 | 2003 |
| Multiple sclerosis normal‐appearing white matter: Pathology–imaging correlations NM Moll, AM Rietsch, S Thomas, AJ Ransohoff, JC Lee, R Fox, A Chang, ... Annals of neurology 70 (5), 764-773, 2011 | 353 | 2011 |
| Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function BO Khatri, S Man, G Giovannoni, AP Koo, JC Lee, B Tucky, F Lynn, ... Neurology 72 (5), 402-409, 2009 | 327 | 2009 |
| Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis A Salter, RJ Fox, SD Newsome, J Halper, DKB Li, P Kanellis, K Costello, ... JAMA neurology 78 (6), 699-708, 2021 | 297 | 2021 |
| Phase 2 trial of ibudilast in progressive multiple sclerosis RJ Fox, CS Coffey, R Conwit, ME Cudkowicz, T Gleason, A Goodman, ... New England Journal of Medicine 379 (9), 846-855, 2018 | 294 | 2018 |
| Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives D Ontaneda, RJ Fox, J Chataway The Lancet Neurology 14 (2), 208-223, 2015 | 268 | 2015 |
| Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV … Strategies for Management of Antiretroviral Therapy (SMART) Study Group The Journal of infectious diseases 197 (8), 1145-1155, 2008 | 260 | 2008 |
| Modulating CCR2 and CCL2 at the blood–brain barrier: relevance for multiple sclerosis pathogenesis D Mahad, MK Callahan, KA Williams, EE Ubogu, P Kivisäkk, B Tucky, ... Brain 129 (1), 212-223, 2006 | 254 | 2006 |
| Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke, JA Hillert, C Walton, ... Neurology 97 (19), e1870-e1885, 2021 | 250 | 2021 |
Amit Bar-OrProfessor, University of PennsylvaniaPotvrđena adresa e-pošte na pennmedicine.upenn.edu
